Bone loss

New Study Explores Ways to Reduce Inflammation and Preserve Bone Health with Prunes

Retrieved on: 
Tuesday, December 12, 2023
Interleukin 8, Diet, Nutrition, Woman, Research, Calcium, Prevalence, Mineral, Ageing, Journal of Nutrition, Food, Monocyte, Protein, Polyphenol, D3, Journal, Interleukin 6, Oxidative stress, Health, University of Georgia, Vitamin, Management, Pennsylvania State University, MPH, University, Osteoporosis, Public, Publication, Bone loss, Inflammation, Dietary supplement, Silviculture, Doctor of Philosophy, Professor

ROSEVILLE, Calif., Dec. 12, 2023 /PRNewswire/ -- A new study published in The Journal of Nutrition shows daily consumption of prunes may reduce inflammation markers connected to bone signaling pathways and reduce the effects of bone loss among postmenopausal women.

Key Points: 
  • ROSEVILLE, Calif., Dec. 12, 2023 /PRNewswire/ -- A new study published in The Journal of Nutrition shows daily consumption of prunes may reduce inflammation markers connected to bone signaling pathways and reduce the effects of bone loss among postmenopausal women.
  • It's important to have a better understanding of how non-pharmacological approaches – like lifestyle and dietary choices—can also impact the progression and mitigation of bone loss."
  • This is an ancillary study of a larger, single-center, parallel-arm, 12-month randomized control trial1 (PRUNE study).
  • This investigation was completed by 183 participants who were split into three groups: control/no prunes (n=70), 50 grams/day prunes (n=67) and 100 grams/day prunes (n=46).

Add California Prunes to daily meals and snacks to benefit your bones, heart, and digestive health

Retrieved on: 
Tuesday, January 31, 2023
Egg, Health, Nutrient, Journal, Antioxidant, Heart, Pulse, Carbohydrate, Magnesium, Water, Eating, Electrolyte, LDL, Neochlorogenic acid, Prune, HDL, Snack, Vitamin K, Chlorogenic acid, Butter, Boron, K2, Food science, Defecation, Journal of Medicinal Food, Woman, Overalls, Vitamin, Sorbitol, Cooking, Seed, Bone loss, Perspiration, Potassium, Nut, Inflammation, Rosenbloom, Viticulture, Silviculture, Dietary supplement

Filled with fibre, vitamins and antioxidants, California prunes are an important functional food to add to your favourite meals and snacks.

Key Points: 
  • Filled with fibre, vitamins and antioxidants, California prunes are an important functional food to add to your favourite meals and snacks.
  • Prunes have a low glycemic index (29), meaning they won’t cause a dramatic spike in blood sugar levels.
  • Dietitian Cara Rosenbloom explains that this beneficial effect is likely due to the combination of the nutrients found in prunes.
  • California Prunes play an important role in digestive health and are well known for their laxative effect.

Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA

Retrieved on: 
Tuesday, January 24, 2023
Hypercalcaemia, Antibody, Malignancy, PHPT, Hypoparathyroidism, Degenerative disease, PTHR1, Parathyroid hormone, Primary hyperparathyroidism, Patient, Calcium, Parathyroid hormone-related protein, Biology, HHM, PTH, Bone loss, Research, Hypophosphatemia, Pharmaceutical industry, Vaccine

LYON, France and CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma (“Amolyt,” “Amolyt Pharma” or the “Company”), a global company specialized in developing innovative therapies for rare endocrine and related diseases, today announced that the Company has entered into a research agreement and licensing option with XOMA Corporation (“XOMA”) for the pre-clinical evaluation of a select set of monoclonal antibodies that arose from XOMA’s legacy discovery efforts as potential treatments for primary hyperparathyroidism (“PHPT”) and humoral hypercalcemia of malignancy (“HHM”). Amolyt has the option to license one or more of these candidates from XOMA for further clinical development worldwide.

Key Points: 
  • LYON, France and CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma (“Amolyt,” “Amolyt Pharma” or the “Company”), a global company specialized in developing innovative therapies for rare endocrine and related diseases, today announced that the Company has entered into a research agreement and licensing option with XOMA Corporation (“XOMA”) for the pre-clinical evaluation of a select set of monoclonal antibodies that arose from XOMA’s legacy discovery efforts as potential treatments for primary hyperparathyroidism (“PHPT”) and humoral hypercalcemia of malignancy (“HHM”).
  • Amolyt has the option to license one or more of these candidates from XOMA for further clinical development worldwide.
  • “We are continuing to build our portfolio for rare endocrine and related diseases while moving, in parallel, our lead program for hypoparathyroidism into a pivotal trial.
  • We look forward to watching Amolyt’s progress, as PHPT and HHM patients are underserved by current standards of care.”

Pearl Street Dental Selects Overjet AI to Enhance Patient Care

Retrieved on: 
Wednesday, January 18, 2023
Disease, Dentistry, Bone loss, Hypertension, Dentist, Periodontal disease, FDA, Health, AI, X-ray, Organization, Diagnosis, DSO, Patient, Diabetes, Practice management, Medical device, DDS

BOSTON, Jan. 18, 2023 /PRNewswire/ -- Pearl Street Dental Partners announced today it is enhancing patient care by adding Overjet's artificial intelligence for X-ray analysis and clinical insights. The dental support organization (DSO) supports 34 affiliated practices in Texas and Oklahoma, each with a mission to provide an exceptional patient experience.

Key Points: 
  • BOSTON, Jan. 18, 2023 /PRNewswire/ -- Pearl Street Dental Partners announced today it is enhancing patient care by adding Overjet's artificial intelligence for X-ray analysis and clinical insights.
  • Overjet is the only dental AI solution that is FDA-cleared to quantify bone level measurements in addition to detecting dental decay and calculus.
  • "A picture's worth a thousand words," said William Jennings, DDS, co-founder and Chief Clinical Officer of Pearl Street Dental.
  • To learn more about how dental support organizations are using Overjet's dental AI platform to lead the change to clinically precise, efficient & patient-centric dental care, visit overjet.com .

Overjet Partners with DECA Dental Group, Providing AI to Improve Patient Outcomes

Retrieved on: 
Tuesday, January 10, 2023
Standard of care, Artificial intelligence, DECA, Partnership, Dentistry, Health, Organization, Dentist, Growth, Patient, Learning, Entrepreneurship, FDA, Bone loss, Dental care, Medical device, DALLAS

By incorporating Overjet's dental AI for X-ray analysis and clinical insights, DECA is taking proactive steps to streamline the diagnostic workflow, create better doctor-patient communication, and improve patient outcomes.

Key Points: 
  • By incorporating Overjet's dental AI for X-ray analysis and clinical insights, DECA is taking proactive steps to streamline the diagnostic workflow, create better doctor-patient communication, and improve patient outcomes.
  • With the goal of improving operational efficiencies and patient outcomes through digital transformation, DECA is the newest dental group to adopt Overjet.
  • "With this partnership, Overjet and DECA are combining the best of dental AI with one of the fastest-growing dental support organizations in the country to improve oral health," said Wardah Inam, Co-Founder and CEO of Overjet.
  • To learn more about how dental support organizations are using Overjet's dental AI platform to lead the change to clinically precise, efficient & patient-centric dental care, visit overjet.com .

Effecti-cal Provides Immediate Bone Support (Without the Unpleasant Side Effects)

Retrieved on: 
Thursday, December 22, 2022
Spouse, Absorption, Immune system, Bone loss, Magnesium, Health, Drug development, Zinc, Vitamin D, Menopause, Constipation, Osteoporosis, Calcium, Woman, Bloating, Dietary supplement

FORT LAUDERDALE, Fla., Dec. 22, 2022 /PRNewswire/ -- Sinoveda is an innovative health brand committed to bringing the strengths of Eastern and Western medicine together. The company has used its proprietary Pharmaceutical Platform Technology, or PPT®, to develop countless medicinal and supplemental solutions that incorporate the ancient wisdom of the East with the impressive precision of the West. One of the most effective of Sinoveda's products to date is its multifaceted calcium supplement Effecti-cal.

Key Points: 
  • One of the most effective of Sinoveda's products to date is its multifaceted calcium supplement Effecti-cal .
  • Bone loss doesn't have early symptoms , making preventative measures especially important.
  • While there are many calcium supplements that can help strengthen bones, some are more effective than others.
  • The need to take calcium supplements for bone support is common.

Mabwell Bioscience Partners with Binnopharm Group to Market 9MW0113, 9MW0321 and 9MW0311 in Russia and Eurasian Economic Union Countries

Retrieved on: 
Tuesday, December 20, 2022
COVID-19, Psoriasis, Commonwealth, Bone loss, Suppository, Disease, Medication, Bone, MOEX, Infection, Adalimumab, NMPA, Uveitis, Woman, EMA, EEU, Patient, Hypercalcaemia, Multiple myeloma, Partnership, Rheumatoid arthritis, Marketing, Risk, FDA, Eurasian Economic Union, MA, LSE, Menopause, Twelfth, Capsule, GMP, Joint Medical Service (Germany), Prostate cancer, Breast cancer, Osteosarcoma, Gel, Fracture, National Medical Products Administration, Tablet, Osteoporosis, Malignancy, SSA, National Key Universities of Vietnam, Economic union, Crohn's disease, CIS, HCM, Ankylosing spondylitis, EU, Pharmaceutical industry, Generic drug, Medical imaging, Dentistry, Dietary supplement, Fine chemical, Denosumab

Mabwell's 9MW0321 and 9MW0311 have been filed for MA approval with the China National Medical Products Administration (NMPA) at the end of 2021.

Key Points: 
  • Mabwell's 9MW0321 and 9MW0311 have been filed for MA approval with the China National Medical Products Administration (NMPA) at the end of 2021.
  • This strategic partnership will leverage Binnopharm Group's strength as one of the biggest Russian pharmaceutical producers with significant manufacturing, registration, sales and marketing capabilities in Russia and Eurasian Economic Union countries.
  • This strategic partnership is the first to expand Mabwell's presence in Russia and Eurasian Economic Union countries, an important market for biosimilars and innovative drugs."
  • This cooperation also represents an important milestone for Binnopharm Group, and for our patients in Russia and Eurasian Economic Union countries that will ensure the social benefit from an increased access to high-quality affordable medicines."

JASON S. GOLDSTEIN OF PARKER WAICHMAN LLP NAMED TO LEADERSHIP ROLE IN NATIONAL EXACTECH LITIGATION

Retrieved on: 
Friday, December 16, 2022
District court, Hip, PSC, Ankle, Order, Lawyer, Truliant Federal Credit Union, 3rd millennium, Connexion, Court, Plaintiff, Bone loss, Parker, Committee, Novation, MDL, Knee, Woman, Patient, Multimedia, MCS, Inflammation, Osteoporosis, Vantage, Practice of law, Medical device

NEW YORK, Dec. 16, 2022 /PRNewswire/ --Jason S. Goldstein, a senior attorney in the Mass Torts Department for the national law firm Parker Waichman LLP, has been named to the Plaintiff's Steering Committee ("PSC") in the multi-district litigation (MDL) involving certain orthopedic devices manufactured by Exactech.

Key Points: 
  • NEW YORK, Dec. 16, 2022 /PRNewswire/ --Jason S. Goldstein, a senior attorney in the Mass Torts Department for the national law firm Parker Waichman LLP, has been named to the Plaintiff's Steering Committee ("PSC") in the multi-district litigation (MDL) involving certain orthopedic devices manufactured by Exactech.
  • Mr. Goldstein brings to the group not only substantial experience in litigating orthopedic device cases, but also the full firepower of the Parker Waichman firm, long involved in multi-district litigation nationwide.
  • Jerry Parker, the founding partner of the firm, commented that "Jason Goldstein is a talented mass torts attorney who has extensive experience in pharmaceutical and medical device litigation.
  • Parker Waichman LLP represents multiple plaintiffs in the Exactech MDL, and expects that the size and scope of the litigation will continue to increase, as more prosthetic failures become known.

Planet DDS Partners with Overjet to Usher in New Era of AI-Powered Dental Imaging

Retrieved on: 
Thursday, December 8, 2022
Data Management, Technology, Health, Radiology, Health Technology, Other Technology, Medical Devices, Software, Artificial Intelligence, Networks, Dental, Cloud, Dentistry, Harvard School of Dental Medicine, DSOS, MIT, Diagnosis, Partnership, Health, Patient, Communication, Bone loss, Periodontal disease, X-ray, FDA, AI, Attention, Practice management, Pathology, Dentist, Insurance, Medical device, Medical imaging, Doctor of Philosophy, Kiwi (bird)

The scalability of the Apteryx XVWeb software, allowing practices to use virtually any imaging device.

Key Points: 
  • The scalability of the Apteryx XVWeb software, allowing practices to use virtually any imaging device.
  • Apteryx XVWeb is a cloud-based dental imaging solution that allows practices to store, view, and optimize clinical images for treatment planning.
  • Planet DDS is committed to creating value for its dental practice clients by solving the most urgent challenges facing todays dental practices in North America.
  • Every day, DSOs, private dental practices, and insurance companies rely on accurate information provided by Overjet to drive care and service to patients.

Home Health Lab Startup Bisu Collaborates With Polaris Dawn to Develop New Ways to Monitor Astronaut Health

Retrieved on: 
Thursday, December 1, 2022
Motion sickness, Bone loss, Starlink, Risk, Sport, Urine, Decompression sickness, Polaris, Weightlessness, Saliva, Dartmouth, Kennedy Space Center, Association of British HealthTech Industries, Ukactive, MD, Geisel School of Medicine, University of Zambia School of Medicine, SpaceX, Health, Research, Bisu, US Sports Camps, Kidney, Kennedy Space Center Launch Complex 39A, Muscle, NASA, Phosphorus, Dragon

As both space accessibility and long-duration human spaceflights increase, keeping crews healthy by providing personalized, targeted countermeasures will be essential.

Key Points: 
  • As both space accessibility and long-duration human spaceflights increase, keeping crews healthy by providing personalized, targeted countermeasures will be essential.
  • Bisu is a startup that helps people improve their health and fitness through lab-grade testing at home.
  • "We're delighted to be working with Polaris Dawn and Prof. Buckey on this pioneering research," says Daniel Maggs , co-founder & CEO at Bisu.
  • The lab has performed work on bone loss, decompression sickness, motion sickness, and psychological countermeasures for isolation and confinement.